INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,053,824 | -25.1% | 97,021 | -9.0% | 0.01% | -20.0% |
| Q2 2023 | $6,751,558 | +14.4% | 106,626 | -2.1% | 0.01% | +11.1% |
| Q1 2023 | $5,900,401 | +0.9% | 108,964 | -1.4% | 0.01% | 0.0% |
| Q4 2022 | $5,847,448 | +15.1% | 110,496 | +1.2% | 0.01% | 0.0% |
| Q3 2022 | $5,082,000 | -19.1% | 109,226 | -0.8% | 0.01% | -10.0% |
| Q2 2022 | $6,282,000 | -1.5% | 110,059 | +5.6% | 0.01% | +25.0% |
| Q1 2022 | $6,378,000 | +25.8% | 104,232 | +7.6% | 0.01% | +33.3% |
| Q4 2021 | $5,069,000 | +43.6% | 96,842 | +2.3% | 0.01% | +20.0% |
| Q3 2021 | $3,529,000 | -11.2% | 94,668 | -2.8% | 0.01% | 0.0% |
| Q2 2021 | $3,976,000 | +17.1% | 97,406 | -2.6% | 0.01% | +25.0% |
| Q1 2021 | $3,395,000 | +6.4% | 100,048 | -0.3% | 0.00% | 0.0% |
| Q4 2020 | $3,191,000 | +25.7% | 100,349 | +1.4% | 0.00% | 0.0% |
| Q3 2020 | $2,538,000 | +19.2% | 98,925 | +19.3% | 0.00% | 0.0% |
| Q2 2020 | $2,129,000 | +72.9% | 82,930 | +3.5% | 0.00% | +33.3% |
| Q1 2020 | $1,231,000 | -47.3% | 80,096 | +17.8% | 0.00% | -25.0% |
| Q4 2019 | $2,334,000 | +355.9% | 68,016 | -0.8% | 0.00% | +300.0% |
| Q3 2019 | $512,000 | -42.5% | 68,579 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $890,000 | +6.6% | 68,579 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $835,000 | +4.5% | 68,579 | -2.3% | 0.00% | 0.0% |
| Q4 2018 | $799,000 | -46.3% | 70,173 | +2.4% | 0.00% | -33.3% |
| Q3 2018 | $1,487,000 | +22.8% | 68,523 | -0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,211,000 | -11.0% | 68,547 | +6.1% | 0.00% | 0.0% |
| Q1 2018 | $1,361,000 | +40.5% | 64,636 | -3.4% | 0.00% | +50.0% |
| Q4 2017 | $969,000 | +13.6% | 66,902 | +23.8% | 0.00% | 0.0% |
| Q3 2017 | $853,000 | +14.7% | 54,025 | -9.8% | 0.00% | 0.0% |
| Q2 2017 | $744,000 | -32.2% | 59,865 | -11.4% | 0.00% | 0.0% |
| Q1 2017 | $1,098,000 | +2.8% | 67,565 | -4.5% | 0.00% | 0.0% |
| Q4 2016 | $1,068,000 | -3.5% | 70,765 | -2.6% | 0.00% | 0.0% |
| Q3 2016 | $1,107,000 | -60.4% | 72,665 | +1.0% | 0.00% | -66.7% |
| Q2 2016 | $2,794,000 | +77.8% | 71,965 | +27.3% | 0.01% | +100.0% |
| Q1 2016 | $1,571,000 | -40.9% | 56,512 | +14.4% | 0.00% | -50.0% |
| Q4 2015 | $2,656,000 | +67.8% | 49,381 | +24.9% | 0.01% | +50.0% |
| Q3 2015 | $1,583,000 | +25.0% | 39,529 | -0.3% | 0.00% | +33.3% |
| Q2 2015 | $1,266,000 | +46.0% | 39,629 | +9.1% | 0.00% | +50.0% |
| Q1 2015 | $867,000 | +54.8% | 36,314 | +14.5% | 0.00% | +100.0% |
| Q4 2014 | $560,000 | +29.3% | 31,714 | +0.4% | 0.00% | 0.0% |
| Q3 2014 | $433,000 | -17.7% | 31,579 | +1.2% | 0.00% | 0.0% |
| Q2 2014 | $526,000 | – | 31,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |